|
| Press Releases |
|
 |
|
| Thursday, June 29, 2023 |
|
|
NanoViricides Announces that Clinical Trials of Its Broad-Spectrum Antiviral Drug NV-CoV-2 Have Begun |
| NanoViricides, Inc. (NYSE American:NNVC) (the "Company") reports that clinical trials of its broad-spectrum antiviral drug NV-CoV-2 began on June 17, 2023 with two oral drug products: (i) NV-CoV-2 Oral Syrup, and (ii) NV-CoV-2 Oral Gummies. more info >> |
|
|
NanoViricides Announces that Clinical Trials of Its Broad-Spectrum Antiviral Drug NV-CoV-2 Have Begun |
| NanoViricides, Inc. (NYSE American:NNVC) (the "Company") reports that clinical trials of its broad-spectrum antiviral drug NV-CoV-2 began on June 17, 2023 with two oral drug products: (i) NV-CoV-2 Oral Syrup, and (ii) NV-CoV-2 Oral Gummies. more info >> |
|
| Wednesday, September 16, 2020 |
|
|
NanoViricides Nominates a Novel Candidate for Advancing Into Clinical Trials for Treatment of COVID-19 |
| NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, today announced that it has nominated a clinical drug candidate for the treatment of COVID-19, thus further advancing its COVID-19 program closer to human clinical trials. more info >> |
|
| Wednesday, May 20, 2020 |
|
|
Strong Effectiveness of NanoViricides Drug Candidates Observed in an Animal Model of Infection by an ACE2-using Human Coronavirus |
| NanoViricides, Inc. (NYSE American: NNVC) (the "Company") a leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, announced today that strong effectiveness against infection by an ACE2-utilizing coronavirus in an animal model has been observed for the drug candidates it is developing against SARS-CoV-2 to treat COVID-19 spectrum of diseases. more info >> |
|
|
Strong Effectiveness of NanoViricides Drug Candidates Observed in an Animal Model of Infection by an ACE2-using Human Coronavirus |
| NanoViricides, Inc. (NYSE American: NNVC) (the "Company") a leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, announced today that strong effectiveness against infection by an ACE2-utilizing coronavirus in an animal model has been observed for the drug candidates it is developing against SARS-CoV-2 to treat COVID-19 spectrum of diseases. more info >> |
|
| Monday, March 16, 2020 |
|
|
Coronavirus Drug Development Update from NanoViricides, Inc. |
| NanoViricides, Inc. (NYSE American: NNVC) (the "Company") a leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, is providing an update on its efforts towards drug development for the current novel coronavirus SARS-CoV-2 that causes COVID-19. more info >> |
|
| Tuesday, March 17, 2020 |
|
|
NanoViricides社、新型コロナウイルス治療薬開発に関する最新情報を発表 |
| 新たなナノ医療プラットフォームを基盤に非常に効果的な抗ウイルス療法の開発でリードするNanoViricides社（NYSE American: NNVC） （以下「当社」）は、COVID-19を引き起こす現在の新型コロナウイルス（SARS-CoV-2）の治療薬開発に向けた取り組みについて最新情報を提供しています。 more info >> |
|
|
NanoViricides公司冠狀病毒藥物開發更新 |
| NanoViricides公司（美國紐約證券交易所交易代碼NNVC）（公司）是基於新型納米藥學平台（公司）開發高效抗病毒治療方法的領先公司，目前正在為造成COVID-19的當前新型冠狀病毒SARS-CoV-2進行藥物開發，現提供其工作相關更新。 more info >> |
|
|
NanoViricides公司冠状病毒药物开发更新 |
| NanoViricides公司（美国纽约证券交易所交易代码 NNVC）（公司）是基于新型纳米药学平台（公司）开发高效抗病毒治疗方法的领先公司，目前正在为造成COVID-19的当前新型冠状病毒SARS-CoV-2进行药物开发，现提供其工作相关更新。 more info >> |
|
| Monday, March 16, 2020 |
|
|
Coronavirus Drug Development Update from NanoViricides, Inc. |
| NanoViricides, Inc. (NYSE American: NNVC) (the "Company") a leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, is providing an update on its efforts towards drug development for the current novel coronavirus SARS-CoV-2 that causes COVID-19. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
遠大中國2025年營收大增27%至28億元 淨利潤3.5億元扭虧為盈
Apr 1, 2026 13:10 HKT/SGT
|
|
|
远大中国2025年营收大增27%至28亿元 净利润3.5亿元扭亏为盈
Apr 1, 2026 13:04 HKT/SGT
|
|
|
芯智控股2025年淨利潤大增60.8%至1.61億港元 AI戰略驅動業績創新高
Apr 1, 2026 12:56 HKT/SGT
|
|
|
芯智控股2025年净利润大增60.8%至1.61亿港元 AI战略驱动业绩创新高
Apr 1, 2026 12:46 HKT/SGT
|
|
|
純利躍升超26倍！品創控股（8066.HK）2025年AI + 私域雙輪開啟增長新週期
Apr 1, 2026 12:37 HKT/SGT
|
|
|
纯利跃升超26倍！品创控股（8066.HK）2025年AI + 私域双轮开启增长新周期
Apr 1, 2026 12:28 HKT/SGT
|
|
|
中國再保舉行2025年度業績發佈會
Apr 1, 2026 11:36 HKT/SGT
|
|
|
聯想控股2025年純利飆升近7倍 科創佈局步入效能釋放期
Apr 1, 2026 11:26 HKT/SGT
|
|
|
联想控股2025年纯利飙升近7倍 科创布局步入效能释放期
Apr 1, 2026 11:19 HKT/SGT
|
|
|
EDA集團公佈2025年全年業績
Apr 1, 2026 10:59 HKT/SGT
|
|
|
VCREDIT Releases 2025 Full-Year Results
Apr 1, 2026 10:29 HKT/SGT
|
|
|
維信金科發佈2025年全年業績：主動調整業務結構 AI深度賦能核心場景
Apr 1, 2026 10:22 HKT/SGT
|
|
|
Legend Holdings 2025 Annual Results: Both Revenue and Net Profit Rise
Apr 1, 2026 10:17 HKT/SGT
|
|
|
Thunderstruck Resources宣布獲得招金國際黃金股份有限公司戰略投資
Apr 1, 2026 06:00 HKT/SGT
|
|
|
Thunderstruck Resources宣布获得招金国际黄金股份有限公司战略投资
Apr 1, 2026 06:00 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
